Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $21.57, but opened at $20.73. Chugai Pharmaceutical shares last traded at $21.8770, with a volume of 8,531 shares traded.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Finally, UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The stock has a market capitalization of $71.18 billion, a price-to-earnings ratio of 23.51 and a beta of 0.59. The business has a fifty day moving average of $21.66 and a 200 day moving average of $24.26.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.The firm had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. On average, equities research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.